Apparent China Study Failure May Not Spell End For Remdesivir COVID-19 Role

Antiviral‘s Role In Severe Patients Is Bigger Question

Apparently disappointing results from the world’s first randomized study for Gilead's remdesivir in COVID-19 have some wondering about whether antiviral can still play a decisive role in some patients with COVID-19.

Corona patient
RESULTS FROM REMDESIVIR CHINA STUDY SHOWS NO SIGNIFICANT IMPROVE IN COVID-19 MORTALITY • Source: Shutterstock

The results from the first randomized, placebo-controlled study for Gilead Sciences Inc.’s remdesivir in China have seemingly disappointed, but some say the repurposed antiviral may still go on to get a regulatory approval for COVID-19.

Originally designed to enroll 237 patients, the study was terminated early due to a lack of participants in Wuhan, the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia